Mitomycin sustained release (UroGen Pharma)

丝裂霉素缓释制剂 (UroGen Pharma)

Report date: 2026/04/30 20:00:20

Base Information

Drug NameMitomycin sustained release (UroGen Pharma)
Drug Alias NameMitomycin C (Urogen Pharma)Mitomycin 0.18% gelMitomycin 0.4% gelMitomycin C mixed with TC GelMitomycin C mixed with TC-3 gel +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA inhibitors
TargetsDNA
Therapy Area/IndicationsUrinary Bladder DiseasesUrethral StrictureUrologic Diseases +[12] 
Global Approved IndicationsUrologic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/04/15
Country/TerritoryBulgariaUnited StatesUkraine +[16] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesUrogen Pharma
China Registration ClassN/A

Develop Information

Active CompaniesUrogen Pharma IncNeopharmUrogen Pharma +[5] 
Inactive CompaniesNational Cancer Institute
Active IndicationsUrethral StrictureUrinary Bladder NeoplasmsUrologic Neoplasms +[5] 
Inactive IndicationsUrinary Bladder DiseasesUrologic DiseasesUrethral Neoplasms +[7] 

Other Information

ATC CodeL01DC03
Related LinksN/A